Jessica Stolee, PhDAssociate Director, Pharma and ASO Analytical Deve at Biogen
Dr. Stolee leads the pharmaceutical and antisense oligonucleotide analytical development group at Biogen, a Massachusetts-based biotechnology company focused on neurological diseases. Her group supports pharmaceutical and oligonucleotide process development and manufacturing and is responsible for evaluating and implementing new technologies for their analysis. Dr. Stolee was one of the primary authors of the CMC portion of Biogen’s first oligonucleotide NDA (Spinraza) and continues to support the global filings. She received her Ph.D. in Chemistry from George Washington University where her work focused on the development of novel ionization methods for mass spectrometry.